{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T01:19:06Z","timestamp":1755998346695},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T00:00:00Z","timestamp":1462924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The efficacy of pemetrexed\u2010based first\u2010line chemotherapy in anaplastic lymphoma kinase (<jats:styled-content style=\"fixed-case\">ALK<\/jats:styled-content>)\u2010positive non\u2010small cell lung cancer (<jats:styled-content style=\"fixed-case\">NSCLC<\/jats:styled-content>) has been demonstrated in several studies; however, there is a lack of data from Chinese populations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The clinicopathological characteristics and treatment outcomes of 52 patients with <jats:styled-content style=\"fixed-case\">ALK<\/jats:styled-content>\u2010positive advanced <jats:styled-content style=\"fixed-case\">NSCLC<\/jats:styled-content> who received pemetrexed as first\u2010line chemotherapy at the Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences were retrospectively reviewed. The primary end points were response rate and progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The gender proportion was balanced and the median age was 51 years (range 26\u201376). Of the 52 patients, 46 (88.5%) had stage <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content> disease, predominantly adenocarcinoma (98.1%). Sixteen patients were current\/former smokers and 36 were never\/light smokers. The most common sites of metastasis were the pleura (36.5%), bone (30.8%), lung (26.9%), and brain (17.3%). The median <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> was 9.5 months (95% confidence interval 7.454\u201311.536). At the time of analysis, partial remission was achieved in 18 (34.6%) patients, stable disease in 26 (50.0%), and progressive disease in eight (15.4%); none of the patients achieved complete remission. The objective response rate was 34.6% and the disease control rate was 84.6%. Common adverse events with pemetrexed were neutropenia (53.8%), nausea and vomiting (51.9%), leukopenia (32.7%), and fatigue (25.0%), mainly at grades 1 or 2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Pemetrexed is efficient and tolerated as first\u2010line treatment for <jats:styled-content style=\"fixed-case\">ALK<\/jats:styled-content>\u2010positive <jats:styled-content style=\"fixed-case\">NSCLC<\/jats:styled-content> in a cohort of Chinese patients and may prove to be an alternative option for the treatment of <jats:styled-content style=\"fixed-case\">ALK<\/jats:styled-content>\u2010positive <jats:styled-content style=\"fixed-case\">NSCLC<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.12353","type":"journal-article","created":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T15:47:14Z","timestamp":1462981634000},"page":"452-458","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical effect of pemetrexed as the first\u2010line treatment in Chinese patients with advanced anaplastic lymphoma kinase\u2010positive non\u2010small cell lung cancer"],"prefix":"10.1111","volume":"7","author":[{"given":"Di","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuezhi","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puyuan","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,5,11]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05945"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.11.025"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.6993"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2012.43"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24181"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0365"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1006448"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70344-3"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214886"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408440"},{"key":"e_1_2_6_12_1","first-page":"1116","article-title":"LY231514, a pyrrolo[2, 3\u2010d]pyrimidine\u2010based antifolate that inhibits multiple folate\u2010requiring enzymes","volume":"57","author":"Shih C","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_6_13_1","first-page":"42","article-title":"Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis","volume":"26","author":"Mendelsohn LG","year":"1999","journal-title":"Semin Oncol"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0375"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70063-3"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.1102"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.163"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31820cf053"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182208fc2"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2015.01.003"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds242"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0318"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.05.003"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.04.009"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0699"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu530"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.10.002"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk196"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182111461"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1759-7714.12353","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.12353","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1759-7714.12353","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.12353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T18:34:52Z","timestamp":1696185292000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.12353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,11]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1111\/1759-7714.12353"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.12353","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,11]]},"assertion":[{"value":"2016-01-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}